Yuliya Mikheeva, MD, PhD, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer harboring BRAF mutations.
Yuliya Mikheeva, MD, PhD of Saint-Petersburg State University, discusses the many challenges oncologists face in treating patients with anaplastic thyroid cancer (ATC) harboring BRAF mutations.
Due to ATC being an aggressive cancer with a poor prognosis and survival rate of only 3-5 months with treatment, the unmet need for novel therapies remains unfilled. For this patient population, especially those with BRAF mutations, limited options exist.
According to Mikheeva, when a patient with ATC, immunotherapy is done in order to find the BRAF mutation. However, is the mutation cannot be found, the prognosis for these patients can be poor. For patients harboring BRAF mutations, targeted therapy may be a possible option to turn to which potentially can increase survival.
Transcription:
0:08 | Anaplastic cancer is not very sensitive to a lot of different therapy strategies and standard chemotherapy has a very low effectiveness and not all patients have a BRAF mutation. Only about 50% to 70% of our patients have BRAF mutations. Of course, we have not enough time to find different approaches for our patients. When we have a patient with anaplastic thyroid cancer, we do the immunochemistry to find the BRAF mutation and for 1 day, about 24 hours, we do the data analysis.
1:17 | In our clinic, we do everything very quickly and if a patient has no BRAF mutation and their volume of tumors is very high, we started the standard chemotherapy without targeted therapy because we have such opportunities like another target therapy. That's why if we can't find a BRAF mutation, the prognosis of these patient is very poor.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More